Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Novel triple immunotherapy combination improves anti-tumor responses in preclinical models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with poor prognosis and limited treatment options.

3 Jan 2023

Researchers identify novel gene mechanism in most aggressive kidney cancers

In a new study from the Johns Hopkins Kimmel Cancer Center, researchers described a novel mechanism of tumor formation in kidney cancers driven by overexpression of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway with loss of the tuberous sclerosis complex (TSC) tumor suppressor gene.

3 Jan 2023

Phase I clinical trial of PAC-1 in patients with end-stage cancers shows promising results

A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers.

22 Dec 2022

Sotorasib achieves meaningful anticancer activity in patients with KRAS G12C-mutated metastatic pancreatic cancer

In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer, according to researchers at The University of Texas MD Anderson Cancer Center.

21 Dec 2022

PCOS increases risk of pancreatic cancer

A new study in confirms that a history of polycystic ovarian syndrome increases a patient’s risk of developing pancreatic cancer.

21 Dec 2022

New method combines injectable radioactive gel with systemic chemotherapy to treat pancreatic cancer

Pancreatic cancer is one of the deadliest types of cancer-;in the U.S., it is estimated that over 88 percent of people will die from the disease within five years of their diagnosis.

20 Dec 2022

BGI cares - 2022 social responsibilities in review

At BGI Genomics, we believe it is our responsibility to not only enhance global health outcomes, but also to help make the places we work and live in better.

From BGI Genomics 20 Dec 2022

Novel immunotherapy offers a promising new strategy to fight hard-to-treat cancers

Scientists at UC San Francisco have engineered T cells to produce a potent anti-cancer cytokine, but only when they encounter tumor cells.

16 Dec 2022

Experimental therapy shows promise as treatment for metastatic colon cancer in preclinical models

An experimental therapy showed promise as treatment for an aggressively spreading type of colorectal cancer in preclinical models, according to a new study by Weill Cornell Medicine investigators.

16 Dec 2022

Researchers identify a new target gene in pancreatic ductal adenocarcinoma

Pancreatic cancer remains one of the deadliest malignancies worldwide. Since five-year survival rate for pancreatic ductal adenocarcinoma (PDAC) is only about 3% in patients, PDAC is very difficult to treat with surgery worldwide.

16 Dec 2022

What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir?

Researchers evaluated the incidence of COVID-19 rebound among SARS-CoV-2 -positive patients treated with oral antiviral drugs such as nirmatrelvir-ritonavir combination and molnupiravir.

12 Dec 2022

How the COVID-19 pandemic impacted the treatment pancreatic cancer patients

Researchers investigates the impact of the COVID-19 pandemic on pancreatic cancer services in England.

11 Dec 2022

Study suggests new anti-KRAS drug as a strong candidate for pancreatic cancer clinical trials

A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine's Abramson Cancer Center showed, suggesting the drug is a strong candidate for clinical trials.

6 Dec 2022

Inactivation of previously unknown gene found to be a likely culprit in the onset of pancreatic cancer

New research out of VCU Massey Cancer Center points to the inactivation of a previously unidentified gene as a likely culprit in the development of pancreatic cancer.

30 Nov 2022

Novel cancer-fighting nanoparticles co-deliver a chemotherapy drug and immunotherapy

University of Pittsburgh researchers have designed cancer-fighting nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, according to a new Nature Nanotechnology study published today.

24 Nov 2022

Over 440 SCI articles published! BGI’s cancer genetics and cell research fuels innovation

BGI has currently published over 440 SCI (Science Citation Index) papers in the field of cancer research, with a cumulative impact factor of over 4,000 points.

From BGI Genomics 23 Nov 2022

Stereotactic MRI-guided adaptive radiation therapy shows promise for treating pancreatic cancer

Findings from a recent prospective study show promising safety and patient outcomes data for locally advanced and borderline resectable pancreatic cancer treatment using ablative Stereotactic MRI-Guided On-table Adaptive Radiation Therapy, also known as SMART.

21 Nov 2022

Research findings could bolster the effectiveness of immune-checkpoint therapy

Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system's T cells to attack tumor cells.

16 Nov 2022

Sanford Burnham Prebys researchers receive ACS grants to advance work on difficult-to-treat cancers

Two faculty members from Sanford Burnham Prebys have been awarded grants from the American Cancer Society (ACS), the largest not-for-profit funding body for scientists studying cancer. Associate Professor Cosimo Commisso, Ph.D., and Assistant Professor Svasti Haricharan, Ph.D., each received competitive awards to advance their work on difficult-to-treat cancers.

15 Nov 2022

New discovery reveals which patients will survive longer after receiving immunotherapy

Patients with head and neck cancer who have more genetic material on chromosome 9 in their cancer cells survive three times longer after receiving immunotherapy than those with less genetic material there, a new study finds.

14 Nov 2022

Pancreatic Cancer News and Research

Further Reading

Novel triple immunotherapy combination improves anti-tumor responses in preclinical models of pancreatic cancer

Researchers identify novel gene mechanism in most aggressive kidney cancers

Phase I clinical trial of PAC-1 in patients with end-stage cancers shows promising results

Sotorasib achieves meaningful anticancer activity in patients with KRAS G12C-mutated metastatic pancreatic cancer

PCOS increases risk of pancreatic cancer

New method combines injectable radioactive gel with systemic chemotherapy to treat pancreatic cancer

BGI cares - 2022 social responsibilities in review

Novel immunotherapy offers a promising new strategy to fight hard-to-treat cancers

Experimental therapy shows promise as treatment for metastatic colon cancer in preclinical models

Researchers identify a new target gene in pancreatic ductal adenocarcinoma

What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir?

How the COVID-19 pandemic impacted the treatment pancreatic cancer patients

Study suggests new anti-KRAS drug as a strong candidate for pancreatic cancer clinical trials

Inactivation of previously unknown gene found to be a likely culprit in the onset of pancreatic cancer

Novel cancer-fighting nanoparticles co-deliver a chemotherapy drug and immunotherapy

Over 440 SCI articles published! BGI’s cancer genetics and cell research fuels innovation

Stereotactic MRI-guided adaptive radiation therapy shows promise for treating pancreatic cancer

Research findings could bolster the effectiveness of immune-checkpoint therapy

Sanford Burnham Prebys researchers receive ACS grants to advance work on difficult-to-treat cancers

New discovery reveals which patients will survive longer after receiving immunotherapy

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News